Boan’s site-specific Integration Cell Line Development Platform BA-Fastcell® Debuted at BPI Asia 2024

Asia's premier biomanufacturing summit, BioProcess International Asia 2024（BPI Asia 2024）,was held in Koyto, Japan from Oct.21-23. Dr. Changlin Dou, the R&D President and Chief Operating Officer of Boan Biotech, was invited to give a presentation titled “BA-Fastcell^®, a Site-specific Integration Cell Line Development Platform, Facilitates Biologics Research & Development”. It is the first time for Boan to unveil its latest achievements in cell line development: BA-Fastcell^® with independent intellectual property rights.

Stable cell line development plays a critical role in biologics development. Therefore, the major global biotech companies have invested huge amount of time and resources to seek new technology to accelerate the cell line development process with more predictable results. Site-specific integration technology can accurately insert exogenous DNA sequences into preselected highly stable and transcriptionally active sites on host cell chromosome. It’s recognized as a key technological trend shaping the future of cell line development. However, it is extremely challenging to establish such a system due to high technological barriers.

Compared with traditional random integration technologies, the site-specific integration technology can significantly reduce cell line screening workload, improve cell line stability and shorten the cell line development cycle, thereby greatly improve the efficiency of biologics R&D while reducing costs. Furthermore, for development of bi- and multi-specific antibodies with complex structures, site-specific integration technology can effectively control product quality early on to improve success rate.

Boan’s BA-Fastcell^® can insert GOI into highly stable and transcriptionally active loci on the chromosome of CHOK1 cells precisely and rapidly; allowing establishment of high-yield monoclonal cell lines within 8 weeks from transfection, comparing to an average of 24-28 weeks with traditional technologies. BA-Fastcell^® platform has also been validated by different molecular types. Pool cells without monoclonal isolation have shown stability in cell growth and protein expression. Such approach can significantly reduce the workload of cell line screening and enable parallel process development during cell line development. Both the development speed and protein expression level of the platform are at an industry-leading level. “We hope BA-Fastcell^® platform can further accelerate the development of both Boan pipeline and partner projects with higher R&D efficiency, therefore better positon Boan to meet the needs of clinical applications and market competition.” Dr. Dou said.

Besides BA-Fastcell^®, Boan also successively developed BA-HIEXcell^® stable cell Line development platform. In January 2024, Boan entered into an agreement with Zencore Biologics Co., Ltd., granting Zencore a non-exclusive right to utilize BA-HIEXcell^® platform for development of antibodies and therapeutic proteins.